drugset
drugset / Trial / NCT01619761

NK Cells in Cord Blood Transplantation

NCT01619761 ↗

Phase 1 Unknown 13 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies. Giving chemotherapy with or without total body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells and natural killer cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

Timeline

Start
2013-05-03
Primary completion
2021-11
Completion
2021-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified — Intravenous
Subject Lenalidomide Other / unclassified — Oral
Subject Melphalan Small molecule — Intravenous
Subject Natural Killer Cell Therapy Cell therapy — Intravenous
Background Fludarabine Small molecule — Intravenous
Background Mycophenolate Mofetil Small molecule — Intravenous
Background Rituximab Monoclonal antibody — Intravenous
Background Tacrolimus Small molecule — Intravenous

Indications

Hodgkins lymphoma acute biphenotypic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement leukemia, myeloid, accelerated-phase myelodysplastic syndrome plasma cell myeloma therapy related acute myeloid leukemia and myelodysplastic syndrome